VANCOUVER, Jan. 22 /CNW/ - Chemokine Therapeutics Corp. (the "Company")
(TSX:CTI, OTCBB:CHKT), a biotechnology company developing chemokine-based
therapies to treat cancer, blood disorders, and vascular diseases, is pleased
to announce that the Company's abstract, "the characterization of the
anti-metastatic activity of a SDF-1 peptide analog in different tumor models",
on its lead compound CTCE-9908 has been accepted by the American Association
for Cancer Research ("AACR") for presentation at its 2007 Annual Meeting being
held in Los Angeles, California on April 14-18, 2007.
